D
Dirk R. Van Bockstaele
Researcher at University of Antwerp
Publications - 54
Citations - 4684
Dirk R. Van Bockstaele is an academic researcher from University of Antwerp. The author has contributed to research in topics: Cell cycle & Bone marrow. The author has an hindex of 28, co-authored 54 publications receiving 4382 citations.
Papers
More filters
Journal ArticleDOI
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer
TL;DR: This review provides an overview of deregulation of the cell cycle in cancer by focusing on mechanisms, i.e. regulation of cyclin‐dependent kinases (CDK) by cyclins, CDK inhibitors and phosphorylating events.
Journal ArticleDOI
Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells.
Viggo Van Tendeloo,Peter Ponsaerts,Filip Lardon,Griet Nijs,Marc Lenjou,Christine Van Broeckhoven,Dirk R. Van Bockstaele,Zwi N. Berneman +7 more
TL;DR: The data clearly demonstrate that Mo-DCs electroporated with mRNA efficiently present functional antigenic peptides to cytotoxic T cells and could serve applications in future DC-based tumor vaccines.
Journal ArticleDOI
Cell cycle and apoptosis.
TL;DR: This review summarizes the different functions of the proteins presently known to control both apoptosis and cell cycle progression and suggests that these important decisions of cell proliferation or cell death are likely to be controlled by more than one signal and are necessary to ensure a proper cellular response.
Journal ArticleDOI
Apoptosis: mechanisms and relevance in cancer.
TL;DR: Dysregulation of apoptosis contributes to many diseases, including cancer, on the other hand, apoptosis-regulating proteins also provide targets for drug discovery and new approaches to the treatment of cancer.
Journal ArticleDOI
Differential effect of jasmonic acid and abscisic acid on cell cycle progression in tobacco BY-2 cells.
TL;DR: It is demonstrated that JA treatment can freeze synchronized BY-2 cells in both the G1 and G2 stages of the cell cycle, suggesting that cell sensitivity toward JA is dependent on thecell cycle phase.